БЕЗОПАСНОСТЬ ТЕРАПИИ ТУБЕРКУЛЕЗА С МНОЖЕСТВЕННОЙ ЛЕКАРСТВЕННОЙ УСТОЙЧИВОСТЬЮ ВОЗБУДИТЕЛЯ У БОЛЬНЫХ ВИЧ-ИНФЕКЦИЕЙ, ПОЛУЧАЮЩИХ АНТИРЕТРОВИРУСНУЮ ТЕРАПИЮ

The review analyzed the studies and meta-analyses devoted the treatment of multiple drug resistant tuberculosis in combination with antiretroviral therapy as a possible risk factor of adverse events and the worst outcomes of therapy. In total, the analysis included 18 sources from the Russian and English databases. Most of the studies did not reveal a confident relation between the simultaneous use of antiretroviral and anti-tuberculosis therapy with second line drugs and increased frequency of adverse events. At the same time, in the largest studies, as well as studies devoted to certain adverse events, the authors managed to prove the existence of such a connection. Data on the structure of adverse events also significantly differed in the results obtained by various authors. Most trials were conducted in African countries with a high prevalence of HIV infection.